Procalcitonin is a Valuable Prognostic Marker in Cardiac Surgery but not Specific for Infection

Abstract

Background: The prognostic value of elevated serum levels of procalcitonin (PCT) in patients early after cardiac surgery on cardiopulmonary bypass (CPB) remains unclear. In a prospective study, we investigated whether PCT is useful as a prognostic marker in cardiac surgery with respect to mortality, complications and infections, and whether PCT is a specific marker for occurrence of infections. Methods: Within 8 months, a subset of 80 high-risk patients (APACHE II-score: 25.1 ± 4.7 (mean ± SD)) out of a consecutive cohort of 776 patients was investigated. Demographic data, operative data and clinical endpoints (mortality, infection, severe complication) were documented. Serum levels of PCT were analyzed preoperatively and at postoperative day 1. Results: Hospital mortality in this high-risk group was 21.3 %, infections occurred in 33.8 % and complications in 58.8 % of the patients. Preoperative PCT was normal in all patients. Postoperative PCT was increased in non-survivors compared to survivors (34.3 ± 7.0 ng/ml vs. 15.9 ± 4.9 ng/ml; p < 0.05), in patients with severe complications (30.3 ± 6.7 ng/ml vs. 5.5 ± 1.4 ng/ml; p < 0.05) and in patients with infections (38.4 ± 11.3 ng/ml vs. 10.8 ± 1.6 ng/ml; p < 0.05). Area under receiver operating characteristic curve for PCT as predictor of mortality, infections and complications was 0.772 (95 %-confidence-interval (CI): 0.651 - 0.894), 0.720 (95 %-CI: 0.603 - 0.837) and 0.861 (95 %-CI: 0.779 - 0.943), respectively. PCT was not different with infectious compared to non-infectious complications. Conclusions: High levels of PCT are associated with mortality, infections, and severe complications early after cardiac surgery using cardiopulmonary bypass and therefore provide a valuable prognostic marker. However, PCT does not discriminate between infectious and non-infectious complications.

Key words

Procalcitonin - cardiopulmonary bypass - cardiac surgery - prognosis - SIRS

References

• 1 Wan S, LeClerc J L, Vincent J L. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies.  Chest. 1997;  112 (3) 676-692
• 2 Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection.  Lancet. 1993;  341 (8844) 515-518
• 3 Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection.  Intensive Care Med. 2000;  26 (9) 1193-1200
• 4 Aouifi A, Piriou V, Blanc P, Bouvier H, Bastien O, Chiari P, Rousson R, Evans R, Lehot J J. Effect of cardiopulmonary bypass on serum procalcitonin and C-reactive protein concentrations.  Br J Anaesth. 1999;  83 (4) 602-607
• 5 Boeken U, Feindt P, Petzold T, Klein M, Micek M, Seyfert U T, Mohan E, Schulte H D, Gams E. Diagnostic value of procalcitonin: the influence of cardiopulmonary bypass, aprotinin, SIRS, and sepsis.  Thorac Cardiovasc Surg. 1998;  46 (6) 348-351
• 6 Hensel M, Volk T, Docke W D, Kern F, Tschirna D, Egerer K, Konertz W, Kox W J. Hyperprocalcitonemia in patients with noninfectious SIRS and pulmonary dysfunction associated with cardiopulmonary bypass.  Anesthesiology. 1998;  89 (1) 93-104
• 7 Kerbaul F, Guidon C, Lejeune P J, Mollo M, Mesana T, Gouin F. Hyperprocalcitonemia is related to noninfectious postoperative severe systemic inflammatory response syndrome associated with cardiovascular dysfunction after coronary artery bypass graft surgery.  J Cardiothorac Vasc Anesth. 2002;  16 (1) 47-53
• 8 Kilger E, Pichler B, Goetz A E, Rank N, Welte M, Morstedt K, Vetter H O, Godje O, Schmitz C, Lamm P, Engelschalk E, Muehlbeyer D, Frey L. Procalcitonin as a marker of systemic inflammation after conventional or minimally invasive coronary artery bypass grafting.  Thorac Cardiovasc Surg. 1998;  46 (3) 130-133
• 9 Lecharny J B, Khater D, Bronchard R, Philip I, Durand G, Desmonts J M, Dehoux M. Hyperprocalcitonemia in patients with perioperative myocardial infarction after cardiac surgery.  Crit Care Med. 2001;  29 (2) 323-325
• 10 Meisner M, Rauschmayer C, Schmidt J, Feyrer R, Cesnjevar R, Bredle D, Tscahikowsky K. Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications.  Intensive Care Med. 2002;  28 (8) 1094-1102
• 11 Rothenburger M, Markewitz A, Lenz T, Kaulbach H G, Marohl K, Kuhlmann W D, Weinhold C. Detection of acute phase response and infection. The role of procalcitonin and C-reactive protein.  Clin Chem Lab Med. 1999;  37 (3) 275-279
• 12 Pilz G, Kreuzer E, Kaab S, Appel R, Werdan K. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients.  Chest. 1994;  105 (1) 76-82
• 13 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.  Crit Care Med. 1992;  20 (6) 864-874
• 14 Hanley J A, McNeil B J. The meaning and use of the area under a receiver operating characteristic (ROC) curve.  Radiology. 1982;  143 (1) 29-36
• 15 Adamik B, Kubler-Kielb J, Golebiowska B, Gamian A, Kubler A. Effect of sepsis and cardiac surgery with cardiopulmonary bypass on plasma level of nitric oxide metabolites, neopterin, and procalcitonin: correlation with mortality and postoperative complications.  Intensive Care Med. 2000;  26 (9) 1259-1267
• 16 Aouifi A, Piriou V, Bastien O, Blanc P, Bouvier H, Evans R, Celard M, Vandenesch F, Rousson R, Lehot J J. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients.  Crit Care Med. 2000;  28 (9) 3171-3176
• 17 Giamarellos-Bourboulis E J, Mega A, Grecka P, Scarpa N, Koratzanis G, Thomopoulos G, Giamarellou H. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?.  Intensive Care Med. 2002;  28 (9) 1351-1356
• 18 Sabat R, Hoflich C, Docke W D, Oppert M, Kern F, Windrich B, Rosenberger C, Kaden J, Volk H D, Reinke P. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with plan-T-cell antibodies.  Intensive Care Med. 2001;  27 (6) 987-991
• 19 Kettelhack C, Hohenberger P, Schulze G, Kilpert B, Schlag P M. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.  Crit Care Med. 2000;  28 (4) 1040-1046
• 20 Nijsten M W, Olinga P, The T H, de Vries E G, Koops H S, Groothuis G M, Limburg P C, ten Duis H J, Moshage H, Hoekstra H J, Bijzet J, Zwaveling J H. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro.  Crit Care Med. 2000;  28 (2) 458-461